Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups

Author:

Mahaffey Kenneth W.1,Jardine Meg J.23,Bompoint Severine2,Cannon Christopher P.45,Neal Bruce267,Heerspink Hiddo J.L.28,Charytan David M.95,Edwards Robert10,Agarwal Rajiv11,Bakris George12,Bull Scott10,Capuano George10,de Zeeuw Dick8,Greene Tom13,Levin Adeera14,Pollock Carol15,Sun Tao10,Wheeler David C.16,Yavin Yshai10,Zhang Hong17,Zinman Bernard18,Rosenthal Norman10,Brenner Barry M.519,Perkovic Vlado220,

Affiliation:

1. Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (K.W.M.).

2. George Institute for Global Health, University of New South Wales, Sydney, Australia (M.J.J., S.B., B.N., H.J.L.H., V.P.).

3. Concord Repatriation General Hospital, Sydney, Australia (M.J.J.).

4. Cardiovascular Division, Brigham & Women’s Hospital, Boston, MA (C.P.C.).

5. Baim Institute for Clinical Research, Boston, MA (D.M.C., C.P.C., B.M.B.).

6. Charles Perkins Centre, University of Sydney, Australia (B.N.).

7. Imperial College London, UK (B.N.).

8. Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, The Netherlands (H.J.L.H., D.d.Z.).

9. Nephrology Division, NYU School of Medicine and NYU Langone Medical Center, New York (D.M.C.).

10. Janssen Research & Development, LLC, Raritan, NJ (R.E., S.B., G.C., T.S., Y.Y., N.R.).

11. Indiana University School of Medicine and VA Medical Center, Indianapolis (R.A.).

12. Department of Medicine, University of Chicago Medicine, IL (G.B.).

13. Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City (T.G.).

14. Division of Nephrology, University of British Columbia, Vancouver, Canada (A.L.).

15. Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St. Leonards, NSW, Australia (C.P.).

16. Department of Renal Medicine, UCL Medical School, London, UK (D.C.W.).

17. Renal Division of Peking University First Hospital, Beijing, China (H.Z.).

18. Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, University of Toronto, ON, Canada (B.Z.).

19. Renal Division and Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (B.M.B.).

20. Royal North Shore Hospital, Sydney, Australia (V.P.).

Abstract

Background: Canagliflozin reduces the risk of kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, but effects on specific cardiovascular outcomes are uncertain, as are effects in people without previous cardiovascular disease (primary prevention). Methods: In CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), 4401 participants with type 2 diabetes mellitus and chronic kidney disease were randomly assigned to canagliflozin or placebo on a background of optimized standard of care. Results: Primary prevention participants (n=2181, 49.6%) were younger (61 versus 65 years), were more often female (37% versus 31%), and had shorter duration of diabetes mellitus (15 years versus 16 years) compared with secondary prevention participants (n=2220, 50.4%). Canagliflozin reduced the risk of major cardiovascular events overall (hazard ratio [HR], 0.80 [95% CI, 0.67–0.95]; P =0.01), with consistent reductions in both the primary (HR, 0.68 [95% CI, 0.49–0.94]) and secondary (HR, 0.85 [95% CI, 0.69–1.06]) prevention groups ( P for interaction=0.25). Effects were also similar for the components of the composite including cardiovascular death (HR, 0.78 [95% CI, 0.61–1.00]), nonfatal myocardial infarction (HR, 0.81 [95% CI, 0.59–1.10]), and nonfatal stroke (HR, 0.80 [95% CI, 0.56–1.15]). The risk of the primary composite renal outcome and the composite of cardiovascular death or hospitalization for heart failure were also consistently reduced in both the primary and secondary prevention groups ( P for interaction >0.5 for each outcome). Conclusions: Canagliflozin significantly reduced major cardiovascular events and kidney failure in patients with type 2 diabetes mellitus and chronic kidney disease, including in participants who did not have previous cardiovascular disease. Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02065791.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3